All In Biotech

Free tool

FAERS Monitor: Veregen

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021902 or its brand name (Veregen, Sinecatechins). Reports on generic versions are filed under their own applications.

Reports

54

Serious

30

56% of reports

Hospitalization

13

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cellulitis6
  • application site pain5
  • drug ineffective5
  • pain4
  • product use issue4
  • application site erythema3
  • erythema3
  • off label use3
  • pruritus3
  • rash3
  • application site discharge2
  • application site pruritus2
  • application site ulcer2
  • condition aggravated2
  • genital herpes2

Reports by year received

View as table
YearReports
20081
20091
20101
20112
20122
20134
20152
20162
20171
201810
20198
20204
20212
20227
20233
20243
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site ulcer21104.5282.91,236
application site discharge2676.9173.5757
genital herpes2510.0130.8570
application site painSignal588.438.4349
cellulitisSignal646.421.8223
application site erythemaSignal344.614.888
application site pruritus234.38.836
product use issueSignal48.33.219
erythemaSignal35.71.97
pruritus33.01.02
rash32.70.92
condition aggravated22.60.71
pain42.51.02
drug ineffective51.50.60
off label use31.30.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.